Visudyne verteporfin: QLT said it expects to complete in mid-2003 enrollment of 360 patients in its ongoing North American Phase III VIO trial of Visudyne to tr

QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C.
Product: Visudyne verteporfin
Business: Ophthalmic

Read the full 110 word article

How to gain access

Continue reading with a
two-week free trial.